Clinical Evaluation of the SONA Saliva C-19 Rapid Self-Test for the Detection of COVID-19

Sars-CoV-2 Infection Clinical Trial

Official title:

Clinical Evaluation of the SONA Saliva C-19 Rapid Self-Test for the Detection of COVID-19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05256589
• Other study ID #: DHF009 - NSHCT
• Status: Completed
• Phase: N/A
• Start date: April 19, 2022
• Est. completion date: May 19, 2022

Study information

• Verified date: March 2023
• Source: Sona Nanotech Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Sona Saliva C-19 Rapid Self-Test is a lateral flow assay intended for detection of the SARS-CoV-2 virus. Performance of the Sona Saliva C-19 Rapid Test assay will be assessed by comparison to an RT-PCR reference method.

Description:

This is a prospective, non-randomized clinical evaluation study being carried out in the intended use population in which fresh saliva samples are collected, tested, and interpreted by lay-users and the results are compared to samples evaluated with an authorized high sensitivity molecular RT-PCR test.

The device to be studied is the Sona Saliva C-19 Rapid Self Test.

Participants will be recruited into the study who present at a NS Health Central Zone COVID-19 PCR testing site for COIVID-19 testing. This study does not involve any additional study visits, and all participants will receive the current standard of care.

Patients will provide their RT-PCR sample as per the established testing processes at the health centre and will receive their results through the standard communication pathway. Self-testing using the Sona assay will be conducted at the COVID -19 testing center by individuals in real time.

The participants will be instructed as to not act on the result of their Sona saliva assay, but rather await the gold standard result of RT-PCR.

A usability questionnaire will also be completed by individuals.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 500
• Est. completion date: May 19, 2022
• Est. primary completion date: April 26, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Aged = 18+ years

2. Presenting at designated NS Health Central Zone COVID-19 PCR testing sites.

3. Receiving a RT-PCR COVID-19 test as per standard of care (nasopharyngeal/mid-turbinate swabs).

4. Unvaccinated, partially vaccinated, fully vaccinated and fully vaccinated-boosted patients

5. Provide written informed consent..

6. Patients may have recently been exposed, in close contact, show no symptoms or may be presenting or have experienced at least one (1) or more signs or symptoms of COVID-19 within = 6 days:

1. Fever as self-described or measured = 38 °C (100.4°F)

2. Chills

3. Cough

4. Shortness of Breath

5. Congestion or Runny Nose

6. Difficulty Breathing

7. Muscle or Body Aches

8. Vomiting

9. Diarrhoea

10. New loss of sense of taste or smell

11. General malaise All patients in whom a test result (positive or negative) is obtained from both the RT-PCR testing and Sona Saliva C-19 Rapid Self-test, will be included in the performance analysis.

Exclusion Criteria:

All patients from whom a non-valid result is obtained from either or both the RT-PCR testing and Sona Saliva C-19 Rapid Self-test will be excluded in the analysis for sensitivity and specificity and will be noted as a test error.

Any rapid tests that produced an invalid test result will be noted as a test error and secondary analysis will be conducted on this cohort of patients to understand any underlying causation.

Patients recruited into the study that are recorded to have consumed anything orally within 30 minutes of conducting a rapid self-test, as per the warnings laid out in the IFU, may be excluded from the analysis to mitigate any interference risks relating to test outcome.

Also, the following:

1. Patients unable to provide a saliva sample for rapid testing

2. Patients unable to provide written consent.

3. Patients previously enrolled in the study

4. Patients undergoing treatment currently and/or within the past thirty (30) days of the study with prescription medication to treat novel Coronavirus SARS-CoV-2 infection

Related Conditions & MeSH terms

• COVID-19
• Sars-CoV-2 Infection

Intervention

Diagnostic Test:
• Sona Saliva C-19 Rapid Self-test
Rapid Antigen diagnostic device performance comparative to RT-PCR

Locations

Country	Name	City	State
Canada	COVID-19 Assessment centre @bayers lake	Halifax	Nova Scotia

Sponsors (2)

Lead Sponsor	Collaborator
Sona Nanotech Inc	Nova Scotia Health Authority

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent Positive Agreement (Sensitivity) and Negative Percent Agreement (Specificity)	Calculate the performance of the Sona Saliva C-19 Rapid Self Test when compared to RT- PCR	35 days from last patient enrolment